A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.

Carmen Balana,Ramon De Las Penas,Juan Manuel Sepúlveda,Miguel J. Gil Gil,Raquel Luque,Oscar Gallego,Gaspar Reynés,Ana Herrero,Pedro Pérez-Segura,Alfonso Berrocal,Jose Maria Vieitez de Prado,Almudena Garcia,Sergio Vázquez Estévez,Sergi Peralta,Isaura Fernández,María Martínez García,Cristina Carrato,Carolina Sanz,S. Villa

A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group.

2014

Carmen Balana
Ramon De Las Penas
Juan Manuel Sepúlveda
Miguel J. Gil Gil
Raquel Luque
Oscar Gallego
Gaspar Reynés
Ana Herrero
Pedro Pérez-Segura
Alfonso Berrocal
Jose Maria Vieitez de Prado
Almudena Garcia
Sergio Vázquez Estévez
Sergi Peralta
Isaura Fernández
María Martínez García
Cristina Carrato
Carolina Sanz
S. Villa

2028 Background: We compared the efficacy and safety of treatment with TMZ or TMZ+BEVprior to and concomitant with radiotherapy in unresectable(GBM) patients. Methods: Between December 2009 and Apr...

Keywords:

Temozolomide
Glioblastoma
Bevacizumab
Randomized controlled trial
Standard treatment
Physical therapy
Medicine
Oncology
Internal medicine
Pathology
Radiation therapy
Concomitant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations